Temple syndrome (or hereditary angioedema) is a rare genetic disorder characterized by recurrent episodes of soft tissue swelling, particularly in the face, extremities, gastrointestinal tract, and airways. These episodes result from dysregulation of the complement system, resulting in excess complement activity, causing vasodilation and increased vascular permeability. Common manifestations include swelling, abdominal pain, dyspnea, and potentially life-threatening airway obstruction. The disorder can significantly impair quality of life, requiring regular medical monitoring and treatment.
History of the disease and interesting historical facts
The history of Temple syndrome research can be traced back to the early 20th century, when the first cases of the disease were documented. In 1963, the genetic origin of the disease was identified, which quickly attracted the attention of the medical community. Initially, the syndrome received various names depending on the manifestations and clinical picture. Interestingly, the first mention of hereditary angioedema dates back to 1882, when a doctor, describing the case of a woman with edema, could not explain the nature of this condition. After the advent of new methods of molecular biology and genetics, researchers were able to find out that the syndrome is caused by a deficiency of certain proteins, including C1 esterase.
Epidemiology
The epidemiology of Temple syndrome indicates its low prevalence in the population. About 1 in 50,000 people suffer from this disease. The disease occurs in both men and women, but women may have a more severe course due to hormonal changes. There are regions with a higher frequency of the syndrome, which is associated with certain genetic factors and traditions of selection in families where cases of angioedema are observed.
Genetic predisposition to this disease
Temple syndrome is a hereditary disorder associated with mutations in the SERPING1 gene, which codes for the protein C1 esterase. Deficiency or dysfunction of this protein leads to excessive activation of the complement system and, as a consequence, to edematous episodes. There are two main forms of the disease: classical and secretory, which differ in the mechanism of transmission and severity of symptoms. It is important to note that the syndrome is inherited in an autosomal dominant manner, which means that only one copy of the mutated gene in one of the parents can be sufficient to transmit the disease to the offspring.
Risk factors for the development of this disease
Risk factors that contribute to the development of Temple syndrome include:
- Heredity – having family members with the disease may indicate an increased risk.
- Genetic mutations – the presence of certain mutations in the SERPING1 gene.
- Hormonal changes – in women, an increase in the frequency of attacks may occur during the premenstrual period or during pregnancy.
- Physical trauma – injuries, surgeries, infections can trigger episodes of swelling.
Diagnosis of this disease
The diagnosis of Temple syndrome is based on clinical manifestations and various diagnostic tests. The main symptoms include:
- Recurring swelling of tissues, especially the face, extremities and esophagus.
- Abdominal pain, vomiting or diarrhea caused by swelling of the gastrointestinal tract.
- Exacerbations associated with physical activity or infections.
Laboratory tests for Temple syndrome include C1 esterase and complement levels. Radiologic studies may be needed to detect swelling of internal organs. It is important to differentiate other forms of angioedema, such as allergic reactions, to rule out other possible causes.
Treatment
Treatment of Temple syndrome includes both general and specific treatment. The main approaches to therapy are:
- Pharmacological treatment – the use of agents such as C1-esterase concentration and inhaled fordant factor, which helps relieve acute symptoms.
- Surgical treatment – in some cases, it may be necessary to drain swelling or correct affected structures.
- Androgen injections to increase C1 esterase levels may be used in chronic disease.
List of medications used to treat this disease
Among the main drugs used to treat Temple syndrome are:
- Cryoprecipitate – to increase the level of C1-esterase in the blood.
- Danazol - for chronic prophylactic treatment.
- Ambroxol – to reduce swelling and improve breathing.
Disease monitoring
Monitoring of Temple syndrome includes regular check-ups and assessment of the patient's condition. The prognosis for life is generally favorable, but the syndrome can have serious complications, such as acute respiratory failure, requiring emergency medical care. Without proper monitoring, exudative episodes can worsen quality of life and lead to disability.
Age-related features of the disease
Temple syndrome can present at any age, but clinical signs often begin in childhood or adolescence. Infants and young children may have a milder presentation, while adolescents may have many more attacks, possibly due to hormonal changes. In older people, clinical signs may be masked by underlying medical conditions, making diagnosis difficult.
Questions and Answers
- What are the main symptoms of Temple syndrome? The main symptoms include recurring tissue swelling, abdominal pain and dyspnea.
- What causes Temple syndrome? The syndrome is caused by mutations in the SERPING1 gene, resulting in C1 esterase deficiency.
- How is the disease diagnosed? Diagnosis is based on clinical symptoms and laboratory tests of C1 esterase levels.
- What is preventive treatment for Temple syndrome? Preventive treatment may include taking androgens to increase C1 esterase levels.
- What are the possible complications of Temple syndrome? Possible complications include airway obstruction and acute allergic reactions.
